Immunogen Inc (IMGN) 2.80 $IMGN
ImmunoGen Announces Departure of Chief Development Officer
BusinessWire - Tue Aug 09, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effective September 2 to pursue an opportunity closer to his primary residence in Pennsylvania.
IMGN: 2.80 (-0.01)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:49PM CDT
ImmunoGen (IMGN) reported a wider-than-expected loss of 51 cents per share in the fourth-quarter of fiscal 2016.
GERN: 2.73 (+0.04), IMGN: 2.80 (-0.01), CORT: 5.35 (+0.02), ANIK: 47.94 (+0.70)
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
BusinessWire - Fri Aug 05, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 2.80 (-0.01)
ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update
BusinessWire - Thu Aug 04, 5:30AM CDT
--Following positive meeting with FDA, Phase 3 FORWARD I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end.
IMGN: 2.80 (-0.01)
Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:30PM CDT
ImmunoGen (IMGN), which is set to report its fourth-quarter fiscal 2016 results on Aug 4, had recorded a negative surprise of 23.33% last quarter.
BMRN: 95.19 (+1.30), IMGN: 2.80 (-0.01)
Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
GlobeNewswire - Wed Jul 27, 3:30PM CDT
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, a position he held since January 2009.
VTAE: 6.84 (-0.07), IMGN: 2.80 (-0.01)
ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021
BusinessWire - Wed Jun 15, 7:58AM CDT
ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of $100 million aggregate principal amount of its 4.50% convertible senior notes due 2021 (the "Notes"
in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act". ImmunoGen also granted the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $15 million aggregate principal amount of the Notes on the same terms and conditions to cover any overallotments.
IMGN: 2.80 (-0.01)
Why is ImmunoGen (IMGN) Stock Down Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 11:11AM CDT
On Tuesday, shares of ImmunoGen Inc. (IMGN) are falling, down over 14% in morning trading after the company proposed a $100 million convertible senior note offering due in 2021.
IMGN: 2.80 (-0.01)
ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021
BusinessWire - Mon Jun 13, 3:01PM CDT
ImmunoGen, Inc. (NASDAQ: IMGN) today announced its intention to offer and sell to the initial purchasers, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2021 (the "Notes" in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act". The sale is expected to close on June 20, 2016. ImmunoGen also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $15 million aggregate principal amount of the Notes on the same terms and conditions to cover over-allotments, if any.
IMGN: 2.80 (-0.01)
Immunogen Shares Down 26.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Fri Jun 10, 1:27AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 1 month, Immunogen has returned 26.73% as of today's recent price of $5.07.
IMGN: 2.80 (-0.01)
ImmunoGen Announces Phase I Cohort Ovarian Cancer Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:57AM CDT
ImmunoGen (IMGN) reported efficacy and safety phase I cohort data evaluating mirvetuximab soravtansine as a single-agent therapy for ovarian cancer.
ANIP: 61.42 (+1.68), IMGN: 2.80 (-0.01), RTRX: 16.35 (+0.33), BMY: 56.76 (-0.63)
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer
BusinessWire - Wed May 18, 4:01PM CDT
--Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
IMGN: 2.80 (-0.01)
Shares of IMGN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 18, 1:30PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 3 weeks, Immunogen has returned 19.08% as of today's recent price of $5.60.
IMGN: 2.80 (-0.01)
ImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:51AM CDT
ImmunoGen (IMGN) reports a loss of 37 cents per share wider than the Zacks Consensus Estimate of a loss of 30 cents.
GILD: 77.42 (-0.96), IMGN: 2.80 (-0.01), AEGR: 1.59 (-0.04)
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 29, 2:33PM CDT
What: ImmunoGen reported its fiscal third-quarter earnings on Friday, and fell as much as 22%, but it wasn't the biotech's revenue or loss that has investors hitting the sell button. So what: For the record, ImmunoGen reported revenue of $19.7...
IMGN: 2.80 (-0.01)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 6.19 (unch), BIIB: 306.03 (+0.40), JNJ: 119.08 (-0.26), BMRN: 95.19 (+1.30), SHPG: 188.50 (+1.32), IMGN: 2.80 (-0.01), BXLT: 46.02 (-0.18), KERX: 4.13 (+0.03), NVS: 78.27 (-0.50)
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.07 (-0.02), IMGN: 2.80 (-0.01), SNY: 38.41 (-0.06)
ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
BusinessWire - Tue Apr 26, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16, 2016. Mr. Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.
IMGN: 2.80 (-0.01)
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
BusinessWire - Mon Apr 11, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 29, 2016, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.
IMGN: 2.80 (-0.01)
ImmunoGen Announces Departure of Chief Development Officer
BusinessWire - Tue Aug 09, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effective September 2 to pursue an opportunity closer to his primary residence in Pennsylvania.
IMGN: 2.80 (-0.01)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:49PM CDT
ImmunoGen (IMGN) reported a wider-than-expected loss of 51 cents per share in the fourth-quarter of fiscal 2016.
GERN: 2.73 (+0.04), IMGN: 2.80 (-0.01), CORT: 5.35 (+0.02), ANIK: 47.94 (+0.70)
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
BusinessWire - Fri Aug 05, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 2.80 (-0.01)
ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly Business Update
BusinessWire - Thu Aug 04, 5:30AM CDT
--Following positive meeting with FDA, Phase 3 FORWARD I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end.
IMGN: 2.80 (-0.01)
Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:30PM CDT
ImmunoGen (IMGN), which is set to report its fourth-quarter fiscal 2016 results on Aug 4, had recorded a negative surprise of 23.33% last quarter.
BMRN: 95.19 (+1.30), IMGN: 2.80 (-0.01)
Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
GlobeNewswire - Wed Jul 27, 3:30PM CDT
Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, a position he held since January 2009.
VTAE: 6.84 (-0.07), IMGN: 2.80 (-0.01)
ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021
BusinessWire - Wed Jun 15, 7:58AM CDT
ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of $100 million aggregate principal amount of its 4.50% convertible senior notes due 2021 (the "Notes"
in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act". ImmunoGen also granted the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $15 million aggregate principal amount of the Notes on the same terms and conditions to cover any overallotments. IMGN: 2.80 (-0.01)
Why is ImmunoGen (IMGN) Stock Down Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 11:11AM CDT
On Tuesday, shares of ImmunoGen Inc. (IMGN) are falling, down over 14% in morning trading after the company proposed a $100 million convertible senior note offering due in 2021.
IMGN: 2.80 (-0.01)
ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021
BusinessWire - Mon Jun 13, 3:01PM CDT
ImmunoGen, Inc. (NASDAQ: IMGN) today announced its intention to offer and sell to the initial purchasers, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2021 (the "Notes"
in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act". The sale is expected to close on June 20, 2016. ImmunoGen also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $15 million aggregate principal amount of the Notes on the same terms and conditions to cover over-allotments, if any. IMGN: 2.80 (-0.01)
Immunogen Shares Down 26.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Fri Jun 10, 1:27AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 1 month, Immunogen has returned 26.73% as of today's recent price of $5.07.
IMGN: 2.80 (-0.01)
ImmunoGen Announces Phase I Cohort Ovarian Cancer Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:57AM CDT
ImmunoGen (IMGN) reported efficacy and safety phase I cohort data evaluating mirvetuximab soravtansine as a single-agent therapy for ovarian cancer.
ANIP: 61.42 (+1.68), IMGN: 2.80 (-0.01), RTRX: 16.35 (+0.33), BMY: 56.76 (-0.63)
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer
BusinessWire - Wed May 18, 4:01PM CDT
--Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
IMGN: 2.80 (-0.01)
Shares of IMGN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 18, 1:30PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 3 weeks, Immunogen has returned 19.08% as of today's recent price of $5.60.
IMGN: 2.80 (-0.01)
ImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:51AM CDT
ImmunoGen (IMGN) reports a loss of 37 cents per share wider than the Zacks Consensus Estimate of a loss of 30 cents.
GILD: 77.42 (-0.96), IMGN: 2.80 (-0.01), AEGR: 1.59 (-0.04)
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 29, 2:33PM CDT
What: ImmunoGen reported its fiscal third-quarter earnings on Friday, and fell as much as 22%, but it wasn't the biotech's revenue or loss that has investors hitting the sell button. So what: For the record, ImmunoGen reported revenue of $19.7...
IMGN: 2.80 (-0.01)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 6.19 (unch), BIIB: 306.03 (+0.40), JNJ: 119.08 (-0.26), BMRN: 95.19 (+1.30), SHPG: 188.50 (+1.32), IMGN: 2.80 (-0.01), BXLT: 46.02 (-0.18), KERX: 4.13 (+0.03), NVS: 78.27 (-0.50)
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.07 (-0.02), IMGN: 2.80 (-0.01), SNY: 38.41 (-0.06)
ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
BusinessWire - Tue Apr 26, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16, 2016. Mr. Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.
IMGN: 2.80 (-0.01)
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
BusinessWire - Mon Apr 11, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 29, 2016, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.
IMGN: 2.80 (-0.01)
